智通财经APP获悉，丹麦制药巨头 诺和诺德 (NVO.US)与人工智能生物科技公司Valo Health周三宣布扩大合作，旨在加速心脏代谢疾病新疗法的研发。 根据 ...

诺和诺德几乎将其与 Valo Health（一家专注于将人工智能应用于药物研发的公司）的研发联盟规模扩大了一倍，在原有的 11 个项目基础上新增了 9 个 ...

today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human ...

Novo Nordisk expanded a deal with Valo Health to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using human data and artificial intelligence. The deal ...